Table 3.
HPV16 variant analysis in oral rinse specimens from patients with HPV16-negative and -positive tumors and for corresponding HPV16-positive tumor samples
Subject | Sample type | Day collected* | HPV16 Variant | Reference HPV16 E6 Sequence position, nt† | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
72 | 131 | 178 | 256 | 307 | 315 | 350 | 478 | 506 | ||||
HPV16-positive tumors | G | A | T | C | G | C | T | C | C | |||
35 | Tumor | -- | E-350T | |||||||||
Oral rinse | 0 | E-350T | ||||||||||
38 | Tumor | -- | Asian | G | ||||||||
Oral rinse | 0 | Asian | G | |||||||||
Oral rinse | 812 | E-350G | G | |||||||||
41 | Tumor | -- | E-350T | del | ||||||||
Oral rinse | 674 | E-350T | del | |||||||||
48 | Tumor | -- | E-350T | |||||||||
Oral rinse | 0 | E-350T | ||||||||||
50 | Tumor | -- | E-350G | G | ||||||||
Oral rinse | 480 | E-350G | G | |||||||||
70 | Tumor | -- | E-G256T | T | G | |||||||
Oral rinse | -41 | E-G256T | T | G | ||||||||
80 | Tumor | -- | E-350T | |||||||||
Oral rinse | 144 | E-350T | ||||||||||
81 | Tumor | -- | E-T131G | G | ||||||||
Oral rinse | -6 | E-350G | G | |||||||||
85 | Tumor | -- | E-T315G | G | ||||||||
Oral rinse | 0 | E-T315G | G | |||||||||
102 | Tumor | -- | E-G506G | G | G | |||||||
Oral rinse | 0 | E-G506G | G | G | ||||||||
123 | Tumor | -- | E-T131G | G | ||||||||
Oral rinse | -6 | E-T131G | G | |||||||||
Oral rinse | 234 | E-350G | G | |||||||||
124 | Tumor | -- | E-350T | |||||||||
Oral rinse | -6 | E-350T | ||||||||||
127 | Tumor | -- | E-T307A | A | ||||||||
Oral rinse | -7 | E-T307A | A | |||||||||
132 | Tumor | -- | E-T131G | G | ||||||||
Oral rinse | -24 | E-T131G | G | |||||||||
HPV16-negative tumors | ||||||||||||
30 | Oral rinse | 640 | E-350T | |||||||||
52 | Oral rinse | 0 | E-350T | |||||||||
96 | Oral rinse | 0 | E-T478A | A |
Relative to date of start of therapy, equal to day 0.
Nucleotide found at specified position in the HPV16 European reference sequence (GenBank, NC 001526). HPV16 E6 coding region is nucleotides (nt) 83–559.